Related references
Note: Only part of the references are listed.Therapeutic potential of CB2 targeting in multiple sclerosis
Fabian Docagne et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Low-dose naltrexone therapy improves active Crohn's disease
Jill P. Smith et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Differential involvement of RelB in morphine-induced modulation of chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes
Cataldo Martucci et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
latrogenic Gilbert syndrome - A strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin
Mark F. McCarty
MEDICAL HYPOTHESES (2007)
Natural history of multiple sclerosis: risk factors and prognostic indicators
Sandra Vukusic et al.
CURRENT OPINION IN NEUROLOGY (2007)
The epidemiology of multiple sclerosis in Europe
M. Pugliatti et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Molecular and cellular basis of cannabinoid and opioid interactions
D Viganò et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2005)
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids
MM Ibrahim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Synergistic interactions between cannabinoid and opioid analgesics
DL Cichewicz
LIFE SCIENCES (2004)
Natural history of primary progressive multiple sclerosis
GC Ebers
MULTIPLE SCLEROSIS JOURNAL (2004)
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
J Zajicek et al.
LANCET (2003)
Attacking pain at its source:: new perspectives on opioids
C Stein et al.
NATURE MEDICINE (2003)
A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients
DW Oslin et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Cannabis use as described by people with multiple sclerosis
SA Page et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2003)
β endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis
M Gironi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2003)
Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross-desensitization and downregulation
M Shapira et al.
BRAIN RESEARCH (2003)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Cannabinoids control spasticity and tremor in a multiple sclerosis model
D Baker et al.
NATURE (2000)
Share Paper
